German Biotech Stock News

Mutares SE KGaA (XTRA:MUX) has just posted another busy year of deal driven activity, with FY 2025 revenue for the latest quarter at €1.6b and net income excluding extra items showing a loss of €32.5m, while the trailing twelve months included a large one off gain of €201.7m that shapes the reported profitability picture. The company has seen quarterly revenue move from €1.25b in Q3 2024 to €1.43b in Q4 2024 and then to €1.53b, €1.61b and €1.59b across the first three quarters of 2025, with...

Dividend decision and fresh board appointments put E.ON (XTRA:EOAN) in focus E.ON (XTRA:EOAN) has drawn fresh investor attention after shareholders approved a dividend of €0.57 per share for fiscal 2025 at the Annual General Meeting on April 23, 2026. On the same day, Helene von Roeder, currently Chief Financial Officer of Merck, and Dr. Dominik von Achten, Chairman of the Managing Board of Heidelberg Materials, were elected to the E.ON SE Supervisory Board for the first time. See our latest...

Bayer plans to present late breaking Phase III OCEANIC STROKE data for asundexian at the 2026 European Stroke Organisation Conference. The company will share 13 abstracts, including subgroup analyses and real world stroke data, focused on its oral Factor XIa inhibitor program. The presentations highlight progress in Bayer's stroke franchise and add detail on a key asset in its late stage pharmaceuticals pipeline. Bayer, traded as XTRA:BAYN, is drawing fresh attention to its pharmaceuticals...

Scout24 (XTRA:G24) has kicked off 2026 with first quarter revenue of €185.4 million and basic EPS of €0.97, alongside net income excluding extra items of €68.5 million, setting a clear marker for how the year is starting to shape up. Over the past year, the company has seen trailing twelve month revenue move from €588.8 million to €692.1 million and basic EPS climb from €2.22 to €3.61, with trailing net margin moving from 28.3% to 37.4%. Investors are watching how these Q1 numbers sit against...

If you are wondering whether Sartorius at around €217 per share is starting to look interesting again, the key question is how its current price compares with a fair value estimate. The stock has edged up 1.1% over the past week and 2.5% over the past month, yet year to date it is still showing a 12.3% decline, with a 4.0% fall over the last year and a 40.2% and 50.0% decline over three and five years respectively. Recent coverage has focused on Sartorius as a key player in life sciences...

Mercedes-Benz Group is selling its European vehicle leasing subsidiary Athlon to BNP Paribas as part of a shift away from capital intensive financial services. The group is also challenging the UK car finance redress scheme, which could lead to significant compensation claims for historic commission arrangements. These moves highlight changing regulatory pressure around auto finance and a sharper focus on core automotive activities such as electrification and software. For investors...

Why the EnergyPathways storage project matters for Siemens Energy Siemens Energy (XTRA:ENR) is in focus after confirming the technical and economic viability of EnergyPathways’ plan for what could become the world’s largest compressed air energy storage project, supported by a £15 million funding package. See our latest analysis for Siemens Energy. At a share price of €175.26, Siemens Energy has posted a 23.42% 1 month share price return and a 42.72% year to date share price return, while its...

Volkswagen has filed a legal challenge against the UK Financial Conduct Authority's proposed £9b car finance redress scheme. The company is seeking independent clarification on how compensation rules should apply to its historical car finance agreements. The case has potential financial implications for Volkswagen and may influence how auto finance complaints are handled across the sector. For shareholders, this legal move comes at a time when Volkswagen, XTRA:VOW3, is already under...

Why Fuchs earnings matter for shareholders Fuchs (XTRA:FPE3) reported first quarter 2026 earnings with sales of €934 million versus €924 million a year earlier, while net income came in at €89 million compared with €77 million. See our latest analysis for Fuchs. The strong first quarter numbers have been met with a sharp move in the share price, with a 1-day share price return of 10.17% and a 30-day share price return of 13.74% indicating building short term momentum. However, the 3-year...

Münchener Rückversicherungs-Gesellschaft in München (XTRA:MUV2) has drawn fresh attention after its annual meeting highlighted record 2025 results, a proposed €24 dividend per share, and long term payout ambitions under the Ambition 2030 plan. See our latest analysis for Münchener Rückversicherungs-Gesellschaft in München. The AGM announcements come after a softer near term patch, with a 7 day share price return of 5.76% and a 1 year total shareholder return of 5.15%. The 5 year total...

PUMA (XTRA:PUM) has appointed former HUGO BOSS CEO Mark Langer as its new Chief Financial Officer. Langer brings extensive experience from Douglas AG and HUGO BOSS AG, where he previously served as both CFO and CEO. The move marks a significant leadership change as PUMA continues its turnaround and brand reset efforts. PUMA enters this management shift with its share price at €24.68 and a mixed return profile that reflects both pressure and recent recovery. The stock is up 14.4% over the...

As European markets face a downturn, with the pan-European STOXX Europe 600 Index ending the week down 2.54% amid geopolitical tensions and economic uncertainties, investors are increasingly looking towards growth companies with significant insider ownership as potential opportunities. In this environment, stocks that combine robust growth prospects with high levels of insider investment can offer a compelling mix of confidence and alignment between company leadership and shareholders.

Adidas is in the spotlight after Sebastian Sawe broke the two hour barrier in the London Marathon, setting a new world record in the newly launched Adizero Adios Pro Evo 3. All top finishers in the race wore the same Adizero Adios Pro Evo 3 model, reinforcing adidas' profile in elite performance running. The record and shoe launch have attracted broad media attention and are being viewed as a key moment for adidas in high end running footwear. For investors looking at XTRA:ADS, this world...

Klöckner & Co (XTRA:KCO) has drawn attention after recent share price moves, with the stock showing mixed short term returns but relatively stronger performance over the past 3 months and year to date. See our latest analysis for Klöckner & Co. Despite a small 1 day share price decline, Klöckner & Co’s recent 30 day and 90 day share price returns are positive, and its 1 year total shareholder return of 83.7% points to strong momentum building over time. If you are looking for other ideas in...

Deutsche Bank (XTRA:DBK) has opened Q1 2026 earnings season with context set by Q4 2025 figures of €6.7b in revenue, basic EPS of €0.21 and net income of €416m, alongside a trailing twelve month EPS of €2.99 on revenue of €29.7b and net income of €5.8b. Over the past few quarters, revenue has ranged from €7.0b to €7.8b, while quarterly basic EPS moved between €0.21 and €1.00 and net income between €416m and €1.97b. This gives investors a clearer view of how profitability is tracking into the...

With the business potentially at an important milestone, we thought we'd take a closer look at INTERSHOP Communications...

As geopolitical tensions and economic uncertainties weigh on European markets, the pan-European STOXX Europe 600 Index has recently seen a decline, with defensive sectors like utilities and telecoms showing resilience. In this environment of heightened risk, identifying undervalued stocks can offer potential opportunities for investors seeking value amid broader market volatility.

Nagarro (XTRA:NA9) has put fresh numbers on the table for FY 2025, with Q3 revenue of €254.6 million and basic EPS of €1.69, while trailing 12 month revenue stands at about €1.0 billion and EPS at €3.76. Over recent quarters, revenue has moved from €244.2 million in Q2 2024 to €252.0 million in Q2 2025, and from €246.7 million in Q4 2024 to €254.6 million in Q3 2025. EPS shifted from €0.90 and €0.59 in those 2024 quarters to €0.65 and €1.69 in the latest 2025 prints. For you as an investor,...

With the business potentially at an important milestone, we thought we'd take a closer look at Wolftank Group AG's...

Wondering whether Dr. Ing. h.c. F. Porsche is attractively priced today or just looks cheap on the surface? This article walks through the numbers so you can judge how the current share price lines up with its underlying value. The stock last closed at €40.53, with returns of 6.6% over the past month but a 14.9% decline year to date and a 3.2% decline over the past year, which may have shifted how the market views its risk and reward trade off. Recent headlines around Dr. Ing. h.c. F...

Allianz (XTRA:ALV) has been shortlisted as a potential buyer for HSBC Life (Singapore) in an ongoing review of HSBC's insurance operations. The process involves several global insurers and focuses on HSBC's Singapore life insurance business. The review is progressing to a new phase where shortlisted bidders, including Allianz, assess the opportunity in more detail. For Allianz, one of Europe's largest insurance groups, being shortlisted for HSBC Life (Singapore) indicates an interest in...

Syntax introduced AI First Application Managed Services for SAP environments, aimed at automating and optimizing day to day SAP operations. Icertis expanded its AI native contract intelligence integration with SAP Ariba to support public sector procurement workflows. Creator Authority broadened its B2B influencer marketing program on LinkedIn, targeting SAP focused decision makers. These announcements tie directly into the core businesses around XTRA:SAP, touching managed services,...

Stratec (XTRA:SBS) FY 2025 Results: Revenue Holds Up As Bottom Line Swings To A Loss Stratec (XTRA:SBS) has wrapped up FY 2025 with fourth quarter revenue of €75.3 million and a basic EPS loss of €0.36, alongside net income excluding extra items of €4.3 million in the red. The company has seen quarterly revenue move from €81.3 million and EPS of €0.95 in Q4 2024 to €75.3 million and a small trailing twelve month EPS loss of €0.02 by Q4 2025, while trailing twelve month net income excluding...

Recent interest in innoscripta (XTRA:1INN) has been sparked by two corporate moves: the relocation of its registered seat to Tutzing and a fresh push into the French R&D tax incentive market via Toulouse. See our latest analysis for innoscripta. These corporate moves come after a mixed stretch for the stock, with a 30 day share price return of 9.65% offset by a 21.43% decline year to date. This suggests that recent momentum is picking up from a weaker few months. If you are curious about what...